Pharvaris N.V. filings document foreign private issuer disclosures for a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists. Form 6-K reports furnish financial results, business updates, investor presentations, clinical-study updates, annual general meeting voting results and materials incorporated by reference into Form F-3 and Form S-8 registration statements.
The filing record also covers capital-structure activity involving ordinary shares and pre-funded warrants, registration rights agreements, underwriting documents, share-based compensation and governance matters. These disclosures frame Pharvaris' development-stage operating expenses, financing activity, shareholder approvals and formal reporting obligations as a Nasdaq-listed foreign private issuer.
Pharvaris N.V. director Robert Glassman reported an exercise-and-sell transaction in company stock. On May 15, 2026, he exercised stock options for 5,333 shares of common stock at a price of $22.31 per share, then sold a total of 10,000 shares in open-market transactions at weighted average prices around $29.82 per share. The sales were executed in multiple trades within price ranges disclosed in the footnotes, and his directly held stake after the transactions was 10,500 common shares. The option exercised was fully vested as of April 11, 2025.
Pharvaris N.V. Chief Technical Ops Officer Stefan Andreas Abele reported an open-market sale of common stock. He sold 8,748 shares at an average price of $29.8199 per share. After the transaction, he directly holds 35,194 shares.
The reported holdings include shares of common stock that were previously acquired upon vesting of restricted stock units on various dates, according to the accompanying footnote.
Pharvaris N.V. Chief Commercial Officer Wim Souverijns sold 10,000 shares of Common Stock in an open-market transaction at a weighted average price of $29.9163 per share. The sale was executed on May 15, 2026 under a pre-arranged Rule 10b5-1 trading plan, and Souverijns held 45,111 shares after the transaction.
Pharvaris N.V. Schedule 13G/A amendment reports that Viking Global-related reporting persons beneficially own 3,653,310 ordinary shares, representing 5.6% of the class. Effective March 31, 2026, David C. Ott retired and was removed as a reporting person.
The filing cites 65,407,822 ordinary shares outstanding as of March 17, 2026 per the issuer's Form 20-F and attributes shared voting and dispositive power over the 3,653,310 shares to Viking Global entities and two executive committee members.
PHVS reports proposed sales under a 10b5-1 plan and a restricted stock unit grant. The filing lists 10b5-1 sales of 23,333 shares on 04/08/2026 for $647,283.26 and 2,292 shares on 04/16/2026 for $65,558.53. It also records 2,292 restricted stock units dated 05/11/2026. Shares outstanding are shown as 65,210,590 as of 05/15/2026.
Morgan Stanley Smith Barney LLC Executive Financial Services filed a Form 144 notice related to proposed sales of Common Stock of PHVS. The excerpt lists 4,667 shares described as Restricted Stock with a 04/11/2025 date and 4,137 shares from a Stock Option Exercise with a 05/15/2026 date.
Pharvaris N.V. Chief Medical Officer Lu Peng reported tax-withholding dispositions of 226 shares of Common Stock connected to restricted stock unit vesting on May 11 and May 12, 2026. On those dates, 109 shares were withheld at $30.09 per share and 117 shares at $29.95 per share to satisfy tax obligations, leaving him with 65,857 shares held directly.
Pharvaris N.V. reported first-quarter 2026 results showing continued investment in late-stage hereditary and acquired angioedema programs and a sizeable cash buffer. Cash and cash equivalents were €247 million as of March 31, 2026, supplemented by a subsequent $132 million underwritten equity offering, which the company says extends its cash runway into 2028.
For the quarter, Pharvaris recorded a net loss of €39.2 million, improved from €46.3 million a year earlier, as finance income offset slightly higher operating expenses. Research and development expenses were €30.2 million, largely driven by late-stage deucrictibant trials, while general and administrative costs rose to €14.1 million as the company prepares for potential commercialization.
Topline data from CHAPTER-3, the pivotal Phase 3 study of deucrictibant XR for prophylaxis of hereditary angioedema attacks, are expected in the third quarter of 2026, and submission of a New Drug Application for deucrictibant IR for on-demand treatment remains planned for the first half of 2026. Enrollment continues in CHAPTER-4 and CREAATE, supporting a potential end-to-end oral treatment portfolio.